Injectable extended-release naltrexone for opioid dependence Reply

被引：1

作者：

Wolfe, Daniel ^{[1
]}

Carrieri, M. P. ^{[2
,3
,4
]}

Dasgupta, Nabarun ^{[5
]}

Bruce, Douglas ^{[6
]}

Wodak, Alex ^{[7
]}

机构：

[1] Open Soc Fdn, Int Harm Reduct Dev Program, New York, NY 10019 USA

[2] INSERM, U912, SE4S, F-13258 Marseille, France

[3] Univ Aix Marseille, IRD, Marseille, France

[4] ORS PACA, Marseille, France

[5] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA

[6] Yale Univ, AIDS Programme, New Haven, CT USA

[7] St Vincents Hosp, Alcohol & Drug Serv, Darlinghurst, NSW 2010, Australia

来源：

LANCET | 2011年 / 378卷 / 9792期

关键词：

PHARMACOTHERAPIES;

D O I：

10.1016/S0140-6736(11)61333-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：666 / 666

页数：1

共 5 条

[1]

[Anonymous], 1978, The Belmont report: Ethical principles and guidelines for the protection of human subjects of research

[2] Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) [J].

Digiusto, E ;

Shakeshaft, A ;

Ritter, A ;

O'Brien, S ;

Mattick, RP .

ADDICTION, 2004, 99 (04) :450-460

[3] Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records [J].

Gibson, Amy E. ;

Degenhardt, Louisa J. .

DRUG AND ALCOHOL REVIEW, 2007, 26 (04) :405-410

[4] Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial [J].

Krupitsky, Evgeny ;

Nunes, Edward V. ;

Ling, Walter ;

Illeperuma, Ari ;

Gastfriend, David R. ;

Silverman, Bernard L. .

LANCET, 2011, 377 (9776) :1506-1513

[5]

*US FDA, 2010, M PSYCH DRUGS ADV CO

← 1 →